| Article ID | Journal | Published Year | Pages | File Type | 
|---|---|---|---|---|
| 3331942 | Hematology/Oncology Clinics of North America | 2009 | 22 Pages | 
Abstract
												Diamond-Blackfan anemia (DBA) is a genetically and clinically heterogeneous disorder characterized by erythroid failure, congenital anomalies, and a predisposition to cancer. Faulty ribosome biogenesis, resulting in proapoptotic erythropoiesis leading to erythroid failure, is hypothesized to be the underlying defect. The genes identified to date that are mutated in DBA all encode ribosomal proteins associated with either the small or large subunit and in these cases haploinsufficiency gives rise to the disease. Extraordinarily robust laboratory and clinical investigations have recently led to demonstrable improvements in clinical care for patients with DBA.
Related Topics
												
													Health Sciences
													Medicine and Dentistry
													Hematology
												
											Authors
												Jeffrey M. Lipton, Steven R. Ellis, 
											